



ABN 53 075 582 740

ASX ANNOUNCEMENT
20 November 2019

AGM RESULTS

Bionomics Limited (ASX:BNO, OTCQB: BNOEF) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company passed four resolutions considered before the Annual General Meeting today and the fifth resolution, which was conditional on the Company receiving 25% of the votes against the adoption of its Remuneration Report (Resolution 1), was withdrawn as the Company did not receive a "second strike" against its Remuneration Report.

The Notice of Annual General Meeting and accompanying documents were lodged with ASX on 18 October 2019.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

Resolution Number	Resolutions	Proxy Votes			
		For	Against	Abstain	Proxy's discretion
1	Adoption of Remuneration Report	43,063,624	3,380,022	109,282,676	1,191,918
2	Re-election of Non-Executive Director Dr Errol De Souza	152,897,211	5,016,799	600,275	1,214,856
3	Re-election of Non-Executive Director Mr Alan Fisher	132,722,374	25,083,127	678,784	1,244,856
4	Election of Non-Executive Director Mr Mitchell Kaye	152,706,810	4,907,597	894,878	1,219,856
5	Spill Resolution	3,468,352	22,030,724	110,211,246	21,207,918

		Poll Results			
Resolution Number	Resolutions	For	Against	Abstain*	Resolution Result
1	Adoption of Remuneration Report	50,681,731	3,386,084	109,290,276	Carried
2	Re-election of Non-Executive Director Dr Errol De Souza	161,143,987	5,017,999	609,222	Carried
3	Re-election of Non-Executive Director Mr Alan Fisher	140,999,150	25,084,327	687,731	Carried
4	Election of Non-Executive Director Mr Mitchell Kaye	160,895,257	4,976,211	899,740	Carried
5	Spill Resolution	-	-	-	Withdrawn as No "Second Strike" on Resolution 1

*Not counted in calculating the required majority on a Poll.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Mr Jack Moschakis

Legal Counsel & Company Secretary

+61 8 8354 6181

jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au